2230 related articles for article (PubMed ID: 36815723)
1. Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy.
Perais J; Agarwal R; Evans JR; Loveman E; Colquitt JL; Owens D; Hogg RE; Lawrenson JG; Takwoingi Y; Lois N
Cochrane Database Syst Rev; 2023 Feb; 2(2):CD013775. PubMed ID: 36815723
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Fenofibrate for diabetic retinopathy.
Kataoka SY; Lois N; Kawano S; Kataoka Y; Inoue K; Watanabe N
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013318. PubMed ID: 37310870
[TBL] [Abstract][Full Text] [Related]
4. Different lasers and techniques for proliferative diabetic retinopathy.
Moutray T; Evans JR; Lois N; Armstrong DJ; Peto T; Azuara-Blanco A
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012314. PubMed ID: 29543992
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
Martinez-Zapata MJ; Salvador I; Martí-Carvajal AJ; Pijoan JI; Cordero JA; Ponomarev D; Kernohan A; Solà I; Virgili G
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD008721. PubMed ID: 36939655
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy.
Dervenis P; Dervenis N; Smith JM; Steel DH
Cochrane Database Syst Rev; 2023 May; 5(5):CD008214. PubMed ID: 37260074
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
Smith JM; Steel DH
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD008214. PubMed ID: 26250103
[TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
Martinez-Zapata MJ; Martí-Carvajal AJ; Solà I; Pijoán JI; Buil-Calvo JA; Cordero JA; Evans JR
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD008721. PubMed ID: 25418485
[TBL] [Abstract][Full Text] [Related]
9. Laser photocoagulation for proliferative diabetic retinopathy.
Evans JR; Michelessi M; Virgili G
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD011234. PubMed ID: 25420029
[TBL] [Abstract][Full Text] [Related]
10. Blood pressure control for diabetic retinopathy.
Do DV; Han G; Abariga SA; Sleilati G; Vedula SS; Hawkins BS
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD006127. PubMed ID: 36975019
[TBL] [Abstract][Full Text] [Related]
11. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.
Richter B; Hemmingsen B; Metzendorf MI; Takwoingi Y
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012661. PubMed ID: 30371961
[TBL] [Abstract][Full Text] [Related]
12. Blood pressure control for diabetic retinopathy.
Do DV; Wang X; Vedula SS; Marrone M; Sleilati G; Hawkins BS; Frank RN
Cochrane Database Syst Rev; 2015 Jan; 1():CD006127. PubMed ID: 25637717
[TBL] [Abstract][Full Text] [Related]
13. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.
Fullerton B; Jeitler K; Seitz M; Horvath K; Berghold A; Siebenhofer A
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD009122. PubMed ID: 24526393
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of adults and children following a first unprovoked seizure.
Neligan A; Adan G; Nevitt SJ; Pullen A; Sander JW; Bonnett L; Marson AG
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD013847. PubMed ID: 36688481
[TBL] [Abstract][Full Text] [Related]
15. Negative pressure wound therapy for treating foot wounds in people with diabetes mellitus.
Liu Z; Dumville JC; Hinchliffe RJ; Cullum N; Game F; Stubbs N; Sweeting M; Peinemann F
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010318. PubMed ID: 30328611
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
17. Glucose targets for preventing diabetic kidney disease and its progression.
Ruospo M; Saglimbene VM; Palmer SC; De Cosmo S; Pacilli A; Lamacchia O; Cignarelli M; Fioretto P; Vecchio M; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD010137. PubMed ID: 28594069
[TBL] [Abstract][Full Text] [Related]
18. Treatment of periodontal disease for glycaemic control in people with diabetes mellitus.
Simpson TC; Weldon JC; Worthington HV; Needleman I; Wild SH; Moles DR; Stevenson B; Furness S; Iheozor-Ejiofor Z
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD004714. PubMed ID: 26545069
[TBL] [Abstract][Full Text] [Related]
19. Non-nutritive sweeteners for diabetes mellitus.
Lohner S; Kuellenberg de Gaudry D; Toews I; Ferenci T; Meerpohl JJ
Cochrane Database Syst Rev; 2020 May; 5(5):CD012885. PubMed ID: 32449201
[TBL] [Abstract][Full Text] [Related]
20. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
Moelands SV; Lucassen PL; Akkermans RP; De Grauw WJ; Van de Laar FA
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD005061. PubMed ID: 30592787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]